Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call

08/06/2021 | 07:30am EDT

MONTREAL, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2021 financial results on Friday, August 13, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date: Friday, August 13, 2021
Time: 8:30 a.m. ET
Telephone: Toll Free: 800-437-2398 or International 1-647-792-1240
Webcast: www.gud-knight.com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.
Replay: An archived replay will be available for 30 days at www.gud-knight.com.
________________________________________

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

CONTACT INFORMATION:

Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia
President and Chief Operating Officer
T: 514.484.4483 ext. 122
F: 514-481-4116
Email: info@knighttx.com
Website: www.gud-knight.com

Knight Therapeutics Inc.
Arvind Utchanah
Chief Financial Officer
T. 514.484.4483 ext. 115
F. 514.481.4116
Email: info@knighttx.com
Website: www.gud-knight.com


Primary Logo


© GlobeNewswire 2021
All news about KNIGHT THERAPEUTICS INC.
09/23INCYTE : Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America
MT
09/23KNIGHT THERAPEUTICS : in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasi..
MT
09/23KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive Supply and Distribution Agreement with N..
MT
09/23INCYTE : Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with ..
AQ
09/23Knight Therapeutics Inc. Enters into Exclusive Supply and Distribution Agreement with I..
CI
08/16KNIGHT THERAPEUTICS : Reports Second Quarter 2021
AQ
08/16NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3-
DJ
08/13KNIGHT THERAPEUTICS : Posts Q2 EPS of C$0.23; Revenue Reaches Record C$65.8 Million
MT
08/13Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
CI
08/13KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Posts Q2 EPS Basic C$0.2..
MT
More news
Financials
Sales 2021 237 M 192 M 192 M
Net income 2021 33,5 M 27,1 M 27,1 M
Net Debt 2021 - - -
P/E ratio 2021 17,9x
Yield 2021 -
Capitalization 639 M 517 M 517 M
Capi. / Sales 2021 2,70x
Capi. / Sales 2022 2,23x
Nbr of Employees 679
Free-Float 81,4%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 5,23 CAD
Average target price 7,73 CAD
Spread / Average Target 47,7%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
James Charles Gale Lead Independent Director
Robert N. Lande Independent Director
Sector and Competitors